Fundraising Fox

Mana Bio

San Francisco, US · 21 employees on LinkedIn · 4 known investors

Find your way into Mana Bio

228 people in our graph share verified history with the Mana Bio team — schools, employers, funds. One of them is your warm intro.

Assaf Arakiunlockedknows Roy Nevo · together at Intel Corporation (overlapped)
×9knows the team · via Intel Corporation
knows the team · via Reichman University
knows the team · via Twist Bioscience

Mana.bio is a biotech company that uses machine learning and high-throughput screening to design lipid nanoparticles for targeted delivery of nucleic acid therapeutics and vaccines. The company aims to unlock RNA-based treatments for genetic diseases with unmet medical needs.

AI & Machine LearningBiotech

Founders & leadership

YDYogev Debbi
Yogev DebbiinCo-Founder & CEO
RNRoy Nevo
Roy NevoinCo-Founder & COORoy Nevo is Co-Founder and CTO of Mana.bio, a biotech company developing machine learning and nanotechnology approaches for nucleic acid therapeutics. He previously led engineering teams at monday.com and Twist Bioscience, bringing over 14 years of experience in interdisciplinary team management and product development.

Investors · 4

Andreessen HorowitzMenlo Park · $500K – $50M
LionBirdTel Aviv · $200K – $500K
NFXSan Francisco · $250K – $5M

Also in the syndicate · 1

Base4 Capital

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

3 people who came through Mana Bio went on to found or lead other companies.

Omri Amirav DroryBoard MemberFounded Renewal BioKira RadinskyScientific Co-FounderFounded Diagnostic RoboticsOmri Amirav-DroryBoard MemberFounded Renewal Bio

Competitors · 4

by search overlap
Nabla Bio7 shared keywordsNabla is a drug development company that applies design discipline and scientific rigor to the development of new medicines. The company focuses on making drug development more systematic and iterative, serving the pharmaceutical and biotech industry.
OmniAb5 shared keywordsOmniAb develops transgenic animal platforms engineered to generate human antibodies for therapeutic drug discovery, serving biopharmaceutical researchers and drug developers.
Nosis Bio5 shared keywordsNosis develops a platform for receptor-targeted delivery of RNA therapeutics to specific cell types, addressing a key bottleneck in RNA drug development. The company aims to reduce the cost and timeline of bringing new RNA medicines to market.
Manifold4 shared keywordsManifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs. The company develops a computational and experimental platform to optimize pharmacokinetics and biodistribution directly in living systems for drug discovery and development.

Companies competing with Mana Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Why NFX Invested in Mana Bio: The TechBio Platform Using AI for Better Drug Deliverynfx.com · Oct 2023

Frequently asked questions

What does Mana Bio do?
Mana.bio is a biotech company that uses machine learning and high-throughput screening to design lipid nanoparticles for targeted delivery of nucleic acid therapeutics and vaccines. The company aims to unlock RNA-based treatments for genetic diseases with unmet medical needs.
Who founded Mana Bio?
Mana Bio was founded by Yogev Debbi, Roy Nevo.
Who are Mana Bio's investors?
Mana Bio's investors include Andreessen Horowitz, LionBird, NFX.
Where is Mana Bio headquartered?
Mana Bio is headquartered in San Francisco, US.